{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:55Z","timestamp":1792025215533,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>Gonorrhea is the second most common sexually transmitted bacterial infection (STI) next to Chlamydia. Untreated cases could results in major complications like pelvic inflammatory disease (PID), ectopic pregnancy, infertility, miscarriage, fetal death and congenital infections. Gonorrhea has been treated with antibiotics for more than eight decades. However, the emergence and spread of antimicrobial resistance (AMR) in gonococcus seriously compromises the management of the disease. The aim of this review was to describe the current developments in the field of azithromycin resistant gonococci.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Literatures published in English in the last 10\u2009years were retrieved from PubMed, SCOPUS, Google scholar, Cochrane library and the Google databases using relevant searching terms.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Gonococcus is capable of using a number of strategies to confer resistance as the bacterium has an extraordinary capacity to alter its genome. So far the accumulated data on the field showed that the world is heading towards a pandemic of extensively drug-resistant (XDR) gonococcus which is now seems to be evolving into a true <jats:italic>\u201csuperbug\u201d.<\/jats:italic> Hence, in the near future gonorrhea may become untreatable on the international basis unless new drugs become available.<\/jats:p>\n<jats:p>An antibiotic resistance in gonococcus has been noted beginning in 1940s against sulfonamides. Since then, resistance has rapidly emerged to penicillins, tetracyclines, macrolides, fluoroquinolones, and cephalosporins. Currently, in most nations, the injectable extended-spectrum cephalosporin (ESC), i.e. ceftriaxone based therapy is the only remaining option for gonorrhea. Based on the WHO and the US-CDC recommendations, countries are increasingly using a combination of cephalosporin and azithromycin for the treatment of gonorrhoea. Azithromycin revolutionized gonoccocal therapy as it shortened treatment time by more than half from 7 to 14\u2009days and improved patient compliance due to high tissue levels and long half-life. However, constantly emerging reports from different parts of the globe showed that <jats:italic>N. gonorrhoeae<\/jats:italic> is developing significant level of resistance against azithromycin, and so far more than 33% level of resistance was reported. Two strategies have been commonly implicated in gonococcal resistance against azithromycin: over expression of an efflux pump (due to mutations at <jats:italic>mtrR<\/jats:italic> coding region) and decreased antimicrobial affinity (due to mutations in genes encoding the 23S ribosomal subunit).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>With no alternative antimicrobial treatment options for gonorrhoea and only a few new drugs in the development pipeline, it is necessary to monitor drug resistance and optimize treatment regimens regularly. Moreover, investigations for novel drugs should be wired.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13756-020-00805-7","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T12:50:56Z","timestamp":1598878256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Azithromycin resistant gonococci: a literature review"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6949-3494","authenticated-orcid":false,"given":"Awoke","family":"Derbie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimtubezinash","family":"Woldeamanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamrat","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"805_CR1","unstructured":"World Health Organization. Global Health Sector Strategy On Sexually Transmitted Infections, 2016\u20132021; Towards Ending STIs. Geneva: WHO; 2016."},{"key":"805_CR2","doi-asserted-by":"publisher","unstructured":"Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis. 5(8):481\u201393. https:\/\/doi.org\/10.1016\/s1473-3099(05)70189-4.","DOI":"10.1016\/s1473-3099(05)70189-4"},{"key":"805_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrmicro3217","volume":"12","author":"MML Namraj Goire","year":"2014","unstructured":"Namraj Goire MML, Chen M, Donovan B, Christopher K, Fairley RG, Kaldor J, Regan D, Ward J, Nissen MD, Sloots TP, Whiley DM. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol. 2014;12:223\u20139. https:\/\/doi.org\/10.1038\/nrmicro3217.","journal-title":"Nat Rev Microbiol"},{"key":"805_CR4","unstructured":"Amanda B. Gonorrhea. 2008. http:\/\/www.austincc.edu\/microbio\/2704w\/ng.htm Accessed 22 Mar 2018."},{"key":"805_CR5","unstructured":"WHO. Sexual and reproductive health: WHO; 2017. http:\/\/www.who.int\/reproductivehealth\/topics\/rtis\/amr-gonorrhoea-on-the-rise\/en\/ Accessed 22 Mar 2018."},{"issue":"3","key":"805_CR6","first-page":"22","volume":"33","author":"IN Bodoev","year":"2015","unstructured":"Bodoev IN, Il'ina EN. Molecular mechanisms of drug resistance Neisseria Gonorrhoeae history and prospects. Mol Gen Mikrobiol Virusol. 2015;33(3):22\u20137.","journal-title":"Mol Gen Mikrobiol Virusol"},{"issue":"4","key":"805_CR7","first-page":"419","volume":"134","author":"UC Achchhe Lal Patel","year":"2011","unstructured":"Achchhe Lal Patel UC, Sachdev D, Sachdeva PN, Bala M, Saluja D. An insight into the drug resistance profile & mechanism of drug resistance in Neisseria gonorrhoeae. Indian J Med Res. 2011;134(4):419\u201331.","journal-title":"Indian J Med Res"},{"issue":"9","key":"805_CR8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/phar.1627","volume":"35","author":"JW Lancaster","year":"2015","unstructured":"Lancaster JW, Mahoney MV, Mandal S, Lawrence KR. Update on treatment options for Gonococcal infections. Pharmacotherapy. 2015;35(9):856\u201368.","journal-title":"Pharmacotherapy."},{"key":"805_CR9","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.806","volume":"3","author":"MN Ezewudo","year":"2015","unstructured":"Ezewudo MN, Joseph SJ, Castillo-Ramirez S, Dean D, del Rio C, Didelot X, et al. Population structure of Neisseria gonorrhoeae based on whole genome data and its relationship with antibiotic resistance. PeerJ. 2015;3:e806. https:\/\/doi.org\/10.7717\/peerj.806.","journal-title":"PeerJ."},{"issue":"3","key":"805_CR10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","volume":"27","author":"M Unemo","year":"2014","unstructured":"Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587\u2013613.","journal-title":"Clin Microbiol Rev"},{"key":"805_CR11","first-page":"1","volume-title":"ASM Microbe 2017","author":"J McConnell","year":"2017","unstructured":"McConnell J. ASM Microbe 2017; 2017. p. 1."},{"key":"805_CR12","volume-title":"Sexual and reproductive health","author":"WHO","year":"2015","unstructured":"WHO. Sexual and reproductive health 2015. http:\/\/www.who.int\/reproductivehealth\/news\/stis-estimates-2015\/en\/ Accessed 22 Mar 2018."},{"key":"805_CR13","doi-asserted-by":"crossref","unstructured":"Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med. 2017;14(7):e1002344. https:\/\/pubmed.ncbi.nlm.nih.gov\/28686231\/.","DOI":"10.1371\/journal.pmed.1002344"},{"issue":"53","key":"805_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12941-016-0166-9","volume":"15","author":"A Brunner","year":"2016","unstructured":"Brunner A, Nikodem E, Jeney C, Szabo D, Marschalko M, Karpati S, et al. Emerging azithromycin-resistance among the Neisseria gonorrhoeae strains isolated in Hungary. Ann Clin Microbiol Antimicrob. 2016;15(53):6. https:\/\/doi.org\/10.1186\/s12941-016-0166-9.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"4","key":"805_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bjm.2017.06.001","volume":"48","author":"C-L APRd","year":"2017","unstructured":"APRd C-L, Barros dos Santos KT, Moreira BM, SEL F, Bonelli RR. Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms and epidemiological aspects of an emerging global threat. Braz J Microbiol. 2017;48(4):617\u201328. https:\/\/doi.org\/10.1016\/j.bjm.2017.06.001.","journal-title":"Braz J Microbiol"},{"issue":"9","key":"805_CR16","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1093\/jac\/dkw182","volume":"71","author":"A Belkacem","year":"2016","unstructured":"Belkacem A, Jacquier H, Goubard A, Mougari F, La Ruche G, Patey O, et al. Molecular epidemiology and mechanisms of resistance of azithromycin-resistant Neisseria gonorrhoeae isolated in France during 2013\u201314. J Antimicrob Chemother. 2016;71(9):2471\u20138. https:\/\/doi.org\/10.1093\/jac\/dkw182.","journal-title":"J Antimicrob Chemother"},{"issue":"321","key":"805_CR17","first-page":"015","volume":"15","author":"MJ Cole","year":"2015","unstructured":"Cole MJ, Spiteri G, Jacobsson S, Pitt R, Grigorjev V, Unemo M. Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance. BMC Infect Dis. 2015;15(321):015\u20131013.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"805_CR18","doi-asserted-by":"crossref","first-page":"018","DOI":"10.1186\/s12879-018-2944-9","volume":"18","author":"S Buder","year":"2018","unstructured":"Buder S, Dudareva S, Jansen K, Loenenbach A, Nikisins S, Sailer A, et al. Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance. BMC Infect Dis. 2018;18(1):018\u20132944.","journal-title":"BMC Infect Dis"},{"key":"805_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2807\/1560-7917.ES2014.19.44.20951","volume":"19","author":"B Bercot","year":"2014","unstructured":"Bercot B, Belkacem A, Goubard A, Mougari F, Sednaoui P, La Ruche G, et al. High-level azithromycin-resistant Neisseria gonorrhoeae clinical isolate in France, march 2014. Euro Surveill. 2014;19:44.","journal-title":"Euro Surveill"},{"issue":"18","key":"805_CR20","first-page":"30035","volume":"22","author":"YH Liu","year":"2018","unstructured":"Liu YH, Huang YT, Liao CH, Hsueh PR. Antimicrobial susceptibilities and molecular typing of neisseria gonorrhoeae isolates at a medical Centre in Taiwan, 2001-2013 with an emphasis on high rate of azithromycin resistance among the isolates. Int J Antimicrob Agents. 2018;22(18):30035\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"805_CR21","first-page":"E179","volume":"40","author":"MM Lahra","year":"2016","unstructured":"Lahra MM, Enriquez RP. Australian Gonococcal surveillance Programme, 1 July to 30 September 2015. Commun Dis Intell Q Rep. 2016;40(1):E179\u201381.","journal-title":"Commun Dis Intell Q Rep"},{"key":"805_CR22","doi-asserted-by":"crossref","unstructured":"KIM M, WELCH, Tanis. Update on azithromycin and cardiac side effects. The Southwest Respiratory and Critical Care Chronicles, [S.l.], v. 2, n. 5, p. 48\u201351, dec. 2013.ISSN 2325\u20139205. 2018. http:\/\/pulmonarychronicles.com\/index.php\/pulmonarychronicles\/article\/view\/107\/224. Accessed 7 April 2018.","DOI":"10.12746\/swrccc.v2i5.107"},{"issue":"3","key":"805_CR23","doi-asserted-by":"crossref","first-page":"0009","DOI":"10.1128\/microbiolspec.EI10-0009-2015","volume":"4","author":"M Unemo","year":"2016","unstructured":"Unemo M, Del Rio C, Shafer WM. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr. 2016;4(3):0009\u20132015.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"805_CR24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1099\/jmm.0.000662","volume":"67","author":"SV Kulkarni","year":"2018","unstructured":"Kulkarni SV, Bala M, Muqeeth SA, Sasikala G, Nirmalkar AP, Thorat R, et al. Antibiotic susceptibility pattern of Neisseria gonorrhoeae strains isolated from five cities in India during 2013-2016. J Med Microbiol. 2018;67(1):22\u20138.","journal-title":"J Med Microbiol"},{"issue":"1","key":"805_CR25","first-page":"1560","volume":"22","author":"CM Wind","year":"2017","unstructured":"Wind CM, van der Loeff MF S, van Dam AP, de Vries HJ, van der Helm JJ. Trends in antimicrobial susceptibility for azithromycin and ceftriaxone in Neisseria gonorrhoeae isolates in Amsterdam, the Netherlands, between 2012 and 2015. Euro Surveill. 2017;22(1):1560\u20137917.","journal-title":"Euro Surveill."},{"issue":"433","key":"805_CR26","first-page":"1471","volume":"14","author":"A Brunner","year":"2014","unstructured":"Brunner A, Nemes-Nikodem E, Mihalik N, Marschalko M, Karpati S, Ostorhazi E. Incidence and antimicrobial susceptibility of Neisseria gonorrhoeae isolates from patients attending the national Neisseria gonorrhoeae reference laboratory of Hungary. BMC Infect Dis. 2014;14(433):1471\u20132334.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"805_CR27","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3201\/eid2305.170088","volume":"23","author":"JR Papp","year":"2017","unstructured":"Papp JR, Abrams AJ, Nash E, Katz AR, Kirkcaldy RD, O'Connor NP, et al. Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii. USA Emerg Infect Dis. 2017;23(5):830\u20132.","journal-title":"USA Emerg Infect Dis"},{"issue":"6","key":"805_CR28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1556\/OH.2015.30079","volume":"156","author":"E Nemes-Nikodem","year":"2015","unstructured":"Nemes-Nikodem E, Brunner A, Toth B, Toth V, Banvolgyi A, Ostorhazi E. Antimicrobal resistance of Neisseria gonorrhoeae strains in Hungary. Orv Hetil. 2015;156(6):226\u20139.","journal-title":"Orv Hetil"},{"issue":"36","key":"805_CR29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2807\/1560-7917.ES.2016.21.36.30335","volume":"21","author":"T Regnath","year":"2016","unstructured":"Regnath T, Mertes T, Ignatius R. Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-West Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins. Euro Surveill. 2016;21(36):1560\u20137917.","journal-title":"Euro Surveill"},{"issue":"8","key":"805_CR30","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.00155-11","volume":"55","author":"SD Mehta","year":"2011","unstructured":"Mehta SD, Maclean I, Ndinya-Achola JO, Moses S, Martin I, Ronald A, et al. Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009. Antimicrob Agents Chemother. 2011;55(8):3882\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"805_CR31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/sextrans-2016-053090","volume":"94","author":"AS Latif","year":"2018","unstructured":"Latif AS, Gwanzura L, Machiha A, Ndowa F, Tarupiwa A, Gudza-Mugabe M, et al. Antimicrobial susceptibility in Neisseria gonorrhoeae isolates from five sentinel surveillance sites in Zimbabwe, 2015-2016. Sex Transm Infect. 2018;94(1):62\u20136.","journal-title":"Sex Transm Infect"},{"issue":"4","key":"805_CR32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/OLQ.0000000000000099","volume":"41","author":"J Vandepitte","year":"2014","unstructured":"Vandepitte J, Hughes P, Matovu G, Bukenya J, Grosskurth H, Lewis DA. High prevalence of ciprofloxacin-resistant gonorrhea among female sex workers in Kampala, Uganda (2008-2009). Sex Transm Dis. 2014;41(4):233\u20137.","journal-title":"Sex Transm Dis"},{"issue":"1","key":"805_CR33","doi-asserted-by":"crossref","first-page":"017","DOI":"10.1186\/s12879-017-2713-1","volume":"17","author":"BT Tadesse","year":"2017","unstructured":"Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, Gonzalez IJ, et al. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17(1):017\u20132713.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"805_CR34","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/jac\/dku176","volume":"69","author":"SJ Leopold","year":"2014","unstructured":"Leopold SJ, van Leth F, Tarekegn H, Schultsz C. Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review. J Antimicrob Chemother. 2014;69(9):2337\u201353.","journal-title":"J Antimicrob Chemother"},{"issue":"152","key":"805_CR35","first-page":"016","volume":"16","author":"JY Liang","year":"2016","unstructured":"Liang JY, Cao WL, Li XD, Bi C, Yang RD, Liang YH, et al. Azithromycin-resistant Neisseria gonorrhoeae isolates in Guangzhou, China (2009-2013): coevolution with decreased susceptibilities to ceftriaxone and genetic characteristics. BMC Infect Dis. 2016;16(152):016\u20131469.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"805_CR36","first-page":"169","volume":"26","author":"W Li","year":"2017","unstructured":"Li W, Zhu BY, Qin SQ, Yang MC, Liang M, He S, et al. Surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae from 2013 to 2015 in Guangxi Province, China. Jpn J Infect Dis. 2017;26(10):169.","journal-title":"Jpn J Infect Dis"},{"key":"805_CR37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12879-017-2472-z","volume":"17","author":"F-X Jiang","year":"2017","unstructured":"Jiang F-X, Lan Q, Le W-J, Su X-H. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from Hefei (2014\u20132015): genetic characteristics of antimicrobial resistance. BMC Infect Dis. 2017;17:366. https:\/\/doi.org\/10.1186\/s12879-017-2472-z.","journal-title":"BMC Infect Dis"},{"key":"805_CR38","doi-asserted-by":"crossref","unstructured":"Yin YP, Han Y, Dai XQ, Zheng HP, Chen SC, Zhu BY, et al. Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: A retrospective study of national surveillance data from 2013 to 2016. PLoS Med. 2018;15(2):e1002499. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5800545\/.","DOI":"10.1371\/journal.pmed.1002499"},{"issue":"45","key":"805_CR39","first-page":"20955","volume":"19","author":"MJ Cole","year":"2014","unstructured":"Cole MJ, Spiteri G, Chisholm SA, Hoffmann S, Ison CA, Unemo M, et al. Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe. Euro Surveill. 2014;19(45):20955.","journal-title":"Euro Surveill"},{"issue":"2","key":"805_CR40","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/AAC.04337-14","volume":"59","author":"RD Kirkcaldy","year":"2015","unstructured":"Kirkcaldy RD, Soge O, Papp JR, Hook EW 3rd, del Rio C, Kubin G, et al. Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the United States by the Gonococcal isolate surveillance project, 2005 to 2013. Antimicrob Agents Chemother. 2015;59(2):998\u20131003.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3\u20134","key":"805_CR41","first-page":"209","volume":"66","author":"B Mlynarczyk-Bonikowska","year":"2014","unstructured":"Mlynarczyk-Bonikowska B, Kujawa M, Mlynarczyk G, Malejczyk M, Majewski S. Resistance to azithromycin of Neisseria gonorrhoeae strains isolated in Poland in 2012-2013 years. Med Dosw Mikrobiol. 2014;66(3\u20134):209\u201314.","journal-title":"Med Dosw Mikrobiol"},{"key":"805_CR42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/sextrans-2012-050905","volume":"89","author":"J-AR Dillon","year":"2014","unstructured":"Dillon J-AR, Trecker MA, Thakur SD. Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: challenges and opportunities. Sex Transm Infect. 2014;89:36\u201341.","journal-title":"Sex Transm Infect"},{"issue":"18","key":"805_CR43","first-page":"30162","volume":"6","author":"M Unemo","year":"2018","unstructured":"Unemo M, Workowski K. Dual antimicrobial therapy for gonorrhoea: what is the role of azithromycin? Lancet Infect Dis. 2018;6(18):30162.","journal-title":"Lancet Infect Dis"},{"key":"805_CR44","volume-title":"Harrison's PRINCIPLES OF INTERNAL MEDICINE. Gonococcal infections","author":"B Fauci","year":"2008","unstructured":"Fauci B, Kasper H, Longo J, et al. Harrison's PRINCIPLES OF INTERNAL MEDICINE. Gonococcal infections. US: The McGraw-Hill Companies; 2008."},{"key":"805_CR45","volume-title":"Review of medical Microbiology and immunology. 1oth ed. gram negative Cocci","author":"L Warren","year":"2008","unstructured":"Warren L. Review of medical Microbiology and immunology. 1oth ed. gram negative Cocci. United States of America: The McGraw-Hill Companies; 2008."},{"issue":"3","key":"805_CR46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/mdr.2010.0199","volume":"17","author":"A Wu","year":"2011","unstructured":"Wu A, Buono S, Katz KA, Pandori MW. Clinical Neisseria gonorrhoeae isolates in the United States with resistance to azithromycin possess mutations in all 23S rRNA alleles and the mtrR coding region. Microb Drug- Resist. 2011;17(3):425\u20137.","journal-title":"Microb Drug- Resist"},{"key":"805_CR47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2807\/ese.13.15.18832-en","volume":"13","author":"SA Chisholm","year":"2008","unstructured":"Chisholm SA, Ison C. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. Euro Surveill. 2008;13:15.","journal-title":"Euro Surveill."},{"issue":"9","key":"805_CR48","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1128\/AAC.00309-10","volume":"54","author":"SA Chisholm","year":"2010","unstructured":"Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother. 2010;54(9):3812\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"805_CR49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/cid\/cix249","volume":"65","author":"CM Wind","year":"2017","unstructured":"Wind CM, de Vries E, van der Loeff MF S, van Rooijen MS, van Dam AP, WHB D, et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin. Clin Infect Dis. 2017;65(1):37\u201345.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"805_CR50","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1128\/AAC.04320-14","volume":"59","author":"K Shigemura","year":"2015","unstructured":"Shigemura K, Osawa K, Miura M, Tanaka K, Arakawa S, Shirakawa T, et al. Azithromycin resistance and its mechanism in Neisseria gonorrhoeae strains in Hyogo, Japan. Antimicrob Agents Chemother. 2015;59(5):2695\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"805_CR51","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1128\/aac.04320-14","volume":"59","author":"K Shigemura","year":"2015","unstructured":"Shigemura K, Osawa K, Miura M, Tanaka K, Arakawa S, Shirakawa T, et al. Azithromycin Resistance and Its Mechanism in Neisseria gonorrhoeae Strains in Hyogo, Japan. Antimicrobial Agents Chemother. 2015;59(5):2695\u20139. https:\/\/doi.org\/10.1128\/aac.04320-14.","journal-title":"Antimicrobial Agents Chemother"},{"issue":"1","key":"805_CR52","first-page":"621","volume":"60","author":"XH Su","year":"2015","unstructured":"Su XH, Wang BX, Le WJ, Liu YR, Wan C, Li S, et al. Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA Gyrase inhibitor, ETX0914 (AZD0914). Antimicrob Agents Chemother. 2015;60(1):621\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"805_CR53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3201\/eid2201.151247","volume":"22","author":"I Martin","year":"2016","unstructured":"Martin I, Sawatzky P, Liu G, Allen V, Lefebvre B, Hoang L, et al. Decline in decreased cephalosporin susceptibility and increase in azithromycin resistance in Neisseria gonorrhoeae, Canada. Emerg Infect Dis. 2016;22(1):65\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"805_CR54","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/infdis\/jiw420","volume":"214","author":"YH Grad","year":"2016","unstructured":"Grad YH, Harris SR, Kirkcaldy RD, Green AG, Marks DS, Bentley SD, et al. Genomic epidemiology of Gonococcal resistance to extended-Spectrum Cephalosporins, macrolides, and Fluoroquinolones in the United States, 2000-2013. J Infect Dis. 2016;214(10):1579\u201387.","journal-title":"J Infect Dis"},{"key":"805_CR55","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing; 29th Ed. CLSI document M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2019","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 29th Ed. CLSI document M100. 2019."},{"key":"805_CR56","doi-asserted-by":"publisher","unstructured":"Khan Z, Siddiqui M, Park S. Current and Emerging Methods of Antibiotic Susceptibility Testing. Diagnostics. 2019;9(49). https:\/\/doi.org\/10.3390\/diagnostics9020049.","DOI":"10.3390\/diagnostics9020049"},{"issue":"1","key":"805_CR57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/QCO.0000000000000025","volume":"27","author":"DA Lewis","year":"2014","unstructured":"Lewis DA. Global resistance of Neisseria gonorrhoeae: when theory becomes reality. Curr Opin Infect Dis. 2014;27(1):62\u20137.","journal-title":"Curr Opin Infect Dis"},{"key":"805_CR58","doi-asserted-by":"crossref","unstructured":"Clifton S, Bolt H, Mohammed H, Town K, Furegato M, Cole M, et al. Prevalence of and factors associated with MDR Neisseria gonorrhoeae in England and Wales between 2004 and 2015: analysis of annual cross-sectional surveillance surveys. J Antimicrob Chemother. 2018;73(4):923\u201332.","DOI":"10.1093\/jac\/dkx520"},{"issue":"3","key":"805_CR59","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/AAC.04536-14","volume":"59","author":"C Hauser","year":"2015","unstructured":"Hauser C, Hirzberger L, Unemo M, Furrer H, Endimiani A. In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother. 2015;59(3):1605\u201311.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"805_CR60","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.04127-14","volume":"59","author":"K Pettus","year":"2015","unstructured":"Pettus K, Sharpe S, Papp JR. In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2015;59(4):2443\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"805_CR61","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/cid\/civ478","volume":"61","author":"IIIEW Hook","year":"2015","unstructured":"Hook IIIEW, Golden M, Jamieson BD, Dixon PB, Harbison HS, Lowens S, et al. A phase 2 trial of Oral Solithromycin 1200 mg or 1000 mg as single-dose Oral therapy for uncomplicated Gonorrhea. Clin Infect Dis. 2015;61(7):1043\u20138. https:\/\/doi.org\/10.1093\/cid\/civ478.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"805_CR62","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro.2017.169","volume":"16","author":"SJ Quillin","year":"2018","unstructured":"Quillin SJ, Seifert HS. Neisseria gonorrhoeae host adaptation and pathogenesis. Nat Rev Microbiol. 2018;16(4):226\u201340.","journal-title":"Nat Rev Microbiol"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-020-00805-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T23:28:21Z","timestamp":1629242901000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-020-00805-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1186\/s13756-020-00805-7","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"assertion":[{"value":"24 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable in this section.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable in this section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}